SALIX ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Salix Pharmaceuticals to Valeant Pharmaceuticals International, Inc.

SAN DIEGO--(BUSINESS WIRE)--

Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Salix Pharmaceuticals, Ltd. SLXP breached their fiduciary duties in connection with the proposed merger of the company with Valeant Pharmaceuticals International, Inc.

Additional Information:

Salix acquires, develops and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases.

On February 22, 2015 Salix and Valeant entered into a merger agreement. Under the terms of the agreement, Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash.

The investigation concerns whether Salix's board failed to satisfy their duties to the Company's shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for the Company's shares of common stock. One Wall Street analyst has a $185.00 price target on Salix stock which is more than the $158.00 offer price.

If you are a shareholder of Salix and believe that the proposed buyout price is too low and you are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471.

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.